OSTX
OSTX
AMEX · Biotechnology

Os Therapies Inc

$1.36
-0.05 (-3.55%)
As of Apr 1, 10:10 PM ET ·
Financial Highlights (FY 2025)
Revenue
10.28M
Net Income
-1,154,434
Gross Margin
33.6%
Profit Margin
-11.2%
Rev Growth
+11.1%
D/E Ratio
0.32
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 33.6% 33.6% 33.6%
Operating Margin -8.8% -8.1% -8.2%
Profit Margin -11.2% -8.8% -11.3%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 10.28M 9.86M 9.80M
Gross Profit 3.45M 3.31M 3.29M
Operating Income -906,627 -795,457 -805,717
Net Income -1,154,434 -865,846 -1,110,362
Gross Margin 33.6% 33.6% 33.6%
Operating Margin -8.8% -8.1% -8.2%
Profit Margin -11.2% -8.8% -11.3%
Rev Growth +11.1% +6.2% +2.7%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 4.74M 4.24M 4.26M
Total Equity 14.89M 15.08M 14.49M
D/E Ratio 0.32 0.28 0.29
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -1,433,621 -1,413,990 -1,277,421
Free Cash Flow -904,387 -870,700 -861,997